This randomized pilot phase IV trial studies octreotide acetate before or after lanreotide acetate in comparing injection site pain in patients with well differentiated neuroendocrine tumors that have spread from where they started to nearby tissue, lymph nodes, or other places in the body. Antihormone therapy, such as octreotide acetate and lanreotide acetate, may fight neuroendocrine tumors by blocking the use of hormones by the tumor cells.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03289741.
PRIMARY OBJECTIVES:
I. To compare injection site pain experienced with octreotide acetate (octreotide long acting release [LAR]) and lanreotide acetate (lanreotide).
SECONDARY OBJECTIVES:
I. To evaluate if patients have a preference for octreotide LAR or lanreotide.
II. To evaluate patient willingness to pay for preferred somatostatin analog (SSA) therapy.
III. To quantify amount of time spent by nurses in clinic to prepare SSA injections.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive octreotide acetate intramuscularly (IM) once every 28 days for 3 months followed by lanreotide acetate deep subcutaneously (SC) once every 28 days for 3 months in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive lanreotide acetate deep SC once every 28 days for 3 months followed by octreotide acetate IM once every 28 days for 3 months in the absence of disease progression or unacceptable toxicity.
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorNitya P. Raj
